Literature DB >> 28867318

Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature.

Ajaya Kumar A1, Abu Abraham Koshy2.   

Abstract

BACKGROUND: Treatment options for recurrent glioma of the brain include chemotherapy, radiotherapy, surgery, and palliation. Temozolomide appears to be effective in patients with recurrent high-grade gliomas. CASE DESCRIPTION: A middle-aged woman presented with a high-grade glioma of corpus callosum. The tumor, a grade 3 anaplastic oligodendroglioma, was excised, and chemoradiotherapy was administered. The patient presented with significant recurrence 5 years later. Repeat surgery and radiation were suggested but refused. She was given temozolomide and dexamethasone intermittently, and levetiracetam was continued. Magnetic resonance imaging performed at 10-month follow-up showed 90% remission.
CONCLUSIONS: There are a few reports in the literature of similar response to temozolomide and levetiracetam. Similar reports give more hope in the treatment of recurrent high grade glioma.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anaplastic glioma; Dexamethasone; High-grade glioma; Levetiracetam; Recurrent glioma; Regression of tumor; Temozolomide

Mesh:

Substances:

Year:  2017        PMID: 28867318     DOI: 10.1016/j.wneu.2017.08.136

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  4 in total

Review 1.  Activation of nuclear factor-κB in the angiogenesis of glioma: Insights into the associated molecular mechanisms and targeted therapies.

Authors:  Jiajie Tu; Yilong Fang; Dafei Han; Xuewen Tan; Haifeng Jiang; Xun Gong; Xinming Wang; Wenming Hong; Wei Wei
Journal:  Cell Prolif       Date:  2020-12-10       Impact factor: 6.831

2.  Optimal Therapies for Recurrent Glioblastoma: A Bayesian Network Meta-Analysis.

Authors:  Wenlin Chen; Yuekun Wang; Binghao Zhao; Penghao Liu; Lei Liu; Yu Wang; Wenbin Ma
Journal:  Front Oncol       Date:  2021-03-29       Impact factor: 6.244

3.  Long Non-Coding RNA GABPB1-AS1 Augments Malignancy of Glioma Cells by Sequestering MicroRNA-330 and Reinforcing the ZNF367/Cell Cycle Signaling Pathway.

Authors:  Xiulong Li; Hongfeng Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-10       Impact factor: 2.570

4.  MiR-483 Targeted SOX3 to Suppress Glioma Cell Migration, Invasion and Promote Cell Apoptosis.

Authors:  Shujing Lu; Zhengyang Yu; Xia Zhang; Lingling Sui
Journal:  Onco Targets Ther       Date:  2020-03-09       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.